Table 1.
Baseline characteristics
| Patients, n (%) | |
| Median age (years) | 64 (range 33–83) |
| Gender | |
| Male | 0 |
| Female | 8 (100) |
| ECOG performance status | |
| 0 | 6 (75) |
| 1 | 2 (25) |
| Disease stage | |
| IV-M1a | 4 (50) |
| IV-M1c | 4 (50) |
| Prior types of therapy | |
| Anti-PD-1 | 8 (100) |
| Anti-CTLA-4 | 8 (100) |
| Chemotherapy | 2 (25) |
| Imiquimod (topical) | 1 (12.5) |
| Trametinib+low dose dabrafenib43 | 2 (25) |
| Median prior lines of therapy | 2 (range 2–5) |
| Molecular analysis | |
| NRASQ61 | 4 (50) |
| SMARC | 2 (25) |
| MEK1K57_G61del | 1 (12.5) |
| GNAQT96S | 1 (12.5) |
CTLA-4, cytotoxic T-lymphocyte associated protein-4; PD-1, programmed cell death protein-1.